MedTrace Logo

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

NCT00038779 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-10-30

No results posted yet for this study

Summary

The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.

Conditions

  • Leukemia
  • Non Hodgkin's Lymphoma
  • Aplastic Anemia

Interventions

PROCEDURE

Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-08-14
Primary Completion
2004-09-20
Completion
2004-09-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038779 on ClinicalTrials.gov